IL319214A - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation

Info

Publication number
IL319214A
IL319214A IL319214A IL31921425A IL319214A IL 319214 A IL319214 A IL 319214A IL 319214 A IL319214 A IL 319214A IL 31921425 A IL31921425 A IL 31921425A IL 319214 A IL319214 A IL 319214A
Authority
IL
Israel
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
IL319214A
Other languages
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL319214A publication Critical patent/IL319214A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL319214A 2022-08-31 2023-08-30 Pharmaceutical formulation IL319214A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022116379 2022-08-31
PCT/EP2023/073764 WO2024047094A1 (en) 2022-08-31 2023-08-30 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
IL319214A true IL319214A (en) 2025-04-01

Family

ID=87930216

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319214A IL319214A (en) 2022-08-31 2023-08-30 Pharmaceutical formulation

Country Status (12)

Country Link
US (1) US20240091231A1 (en)
EP (1) EP4580606B1 (en)
JP (1) JP2025527807A (en)
KR (1) KR20250054108A (en)
CN (1) CN119789849A (en)
AR (1) AR130351A1 (en)
AU (1) AU2023332020A1 (en)
CA (1) CA3266275A1 (en)
IL (1) IL319214A (en)
MX (1) MX2025002184A (en)
TW (1) TW202425997A (en)
WO (1) WO2024047094A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026145414A1 (en) * 2024-12-31 2026-07-09 石药集团中奇制药技术(石家庄)有限公司 Pharmaceutical composition comprising tricyclic heteroaryl compound, preparation method therefor and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
US6524618B1 (en) * 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
HU227317B1 (en) * 2003-11-25 2011-03-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Enteric coated tablet containing pantoprazole
GB0620005D0 (en) * 2006-10-10 2006-11-22 Glaxo Group Ltd Compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
AU2013204533B2 (en) * 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
WO2017064814A1 (en) * 2015-10-16 2017-04-20 持田製薬株式会社 Dienogest-containing tablet
CN113645961A (en) * 2019-03-13 2021-11-12 诺华股份有限公司 Pharmaceutical composition
MX2022014901A (en) * 2020-06-02 2023-01-18 Nerre Therapeutics Ltd Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs.
TW202342040A (en) * 2022-02-21 2023-11-01 瑞士商諾華公司 Pharmaceutical formulation

Also Published As

Publication number Publication date
CN119789849A (en) 2025-04-08
WO2024047094A1 (en) 2024-03-07
US20240091231A1 (en) 2024-03-21
EP4580606B1 (en) 2026-05-27
EP4580606A1 (en) 2025-07-09
TW202425997A (en) 2024-07-01
JP2025527807A (en) 2025-08-22
AR130351A1 (en) 2024-11-27
AU2023332020A1 (en) 2025-04-17
MX2025002184A (en) 2025-04-02
CA3266275A1 (en) 2024-03-07
KR20250054108A (en) 2025-04-22

Similar Documents

Publication Publication Date Title
IL290894A (en) Pharmaceutical formulation
EP4238556A4 (en) Gastroretentive pharmaceutical dosage form
IL300090A (en) Pharmaceutical compositions comprising venglustat
GB202010230D0 (en) Pharmaceutical formulation
IL327150A (en) Pharmaceutical compositions
GB202100526D0 (en) Pharmaceutical formulation
GB202005282D0 (en) Pharmaceutical Formulations
ZA202212663B (en) Pharmaceutical formulations
IL314206A (en) Pharmaceutical formulation
IL326970A (en) Pharmaceutical compositions comprising nipocalimab
GB202104097D0 (en) Pharmaceutical compounds
GB202307626D0 (en) Pharmaceutical formulations
IL297081A (en) Pharmaceutical formulation
CA3266275A1 (en) Pharmaceutical formulation
GB201906473D0 (en) Pharmaceutical formulation
IL314046A (en) Ribociclib pharmaceutical compositions
IL321640A (en) Pharmaceutical formulation
GB202216467D0 (en) Pharmaceutical formulation
GB202203764D0 (en) Pharmaceutical formulation
GB202003108D0 (en) Pharmaceutical formulations
IL289927A (en) New pharmaceutical formulation
GB202001439D0 (en) Drug formulations
GB202510537D0 (en) Pharmaceutical formulation
IL308250A (en) Pharmaceutical formulations
GB202112820D0 (en) Pharmaceutical formulations